Education
About Us
Working with TipRanks
Follow Us
Gri Bio, Inc. (GRI)
NASDAQ:GRI
GRI Stock Chart & Stats
$0.28
-$0.06(-7.48%)
At close: 4:00 PM EST
$0.28
-$0.06(-7.48%)
Day’s Range― - ―
52-Week Range$0.18 - $11.91
Previous CloseN/A
Volume96.89K
Average Volume (3M)3.85M
Market Cap
$2.98M
Enterprise Value-$3.44M
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)$114.00K
Price to Earnings (P/E)―
Beta2.35
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding15,016,434
10 Day Avg. Volume2,019,210
30 Day Avg. Volume3,851,509
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.11
P/FCF Ratio-0.30
Enterprise Value/Market Cap-1.16
Enterprise Value/Revenue-0.12
Enterprise Value/Gross Profit860.61
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$23.00Price Target Upside8114.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst Valuation And SentimentAnalyst maintains a buy rating and raised the 12-month price target, indicating belief that current valuation offers meaningful upside relative to risk.
Clinical Trial ResultsPhase 2a data showed a clean safety profile and biomarker signals suggesting GRI-0621 may slow or reverse lung fibrosis, supporting further advanced-stage testing.
Market OpportunityIdiopathic pulmonary fibrosis represents a large and growing market with tens of thousands of new cases annually, implying substantial commercial potential if an effective therapy is approved.
Bears Say
Development And Regulatory RiskLead programs still face long development and commercialization paths, exposing the company to high clinical trial and regulatory failure risk before generating material revenue.
Liquidity RiskLimited cash on hand increases the likelihood that additional financing will be required, which could dilute shareholders or divert focus from development milestones.
Pipeline Concentration RiskDependence on a small pipeline of two drugs concentrates outcome risk, so setbacks in a single program could significantly impact the stock.
GRI Bio News
GRI FAQ
What was Gri Bio, Inc.’s price range in the past 12 months?
Gri Bio, Inc. lowest stock price was $0.18 and its highest was $11.91 in the past 12 months.
What is Gri Bio, Inc.’s market cap?
Gri Bio, Inc.’s market cap is $2.98M.
When is Gri Bio, Inc.’s upcoming earnings report date?
Gri Bio, Inc.’s upcoming earnings report date is May 20, 2026 which is in 113 days.
How were Gri Bio, Inc.’s earnings last quarter?
Gri Bio, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.31 by -$0.08.
Is Gri Bio, Inc. overvalued?
According to Wall Street analysts Gri Bio, Inc.’s price is currently Undervalued.
Does Gri Bio, Inc. pay dividends?
Gri Bio, Inc. does not currently pay dividends.
What is Gri Bio, Inc.’s EPS estimate?
Gri Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gri Bio, Inc. have?
Gri Bio, Inc. has 15,016,434 shares outstanding.
What happened to Gri Bio, Inc.’s price movement after its last earnings report?
Gri Bio, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.31. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Gri Bio, Inc.?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gri Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$23.00
▲(8114.29% Upside)
Technical Analysis
Ownership Overview
4.11%
Insiders
0.19% Mutual Funds
0.72% Other Institutional Investors
94.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---